Phase II EV-201 study demonstrates 52% ORR in urothelial cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase II clinical study EV-201 evaluating the antibody-drug conjugate Padcev (enfortumab vedotinejfv) for treatment of urothelial cancer demonstrated a 52% overall response rate in the second cohort.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login